ACXP

STATEN ISLAND, N.Y., Nov. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious or life-threatening bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2026.   Highlights of the third quarter ended September 30, 2026, or in some cases shortly thereafter, include:In July 2026, the Company's R&D team met with the FDA for the purpose of seeking their guidance on our plan to conduct a single phase 3 study in acute CDI and its acceptability as a pivotal trial for filing a New Drug Application (or NDA

10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., Oct. 26, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life threatening bacterial infections, announced today that the Company will discuss its third quarter 2026 financial results on Thursday, November 12, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                   Thursday, November 12, 2026Time:                     8:00

Publication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid in a murine neutropenic thigh infection modelStructural molecular modification of molecules related to ibezapolstat (IBZ) improved solubility and systemic exposure of novel Pol IIIC inhibitors with all three tested Pol IIIC inhibitors reduced MRSA burden in a neutropenic mouse thigh modelPol IIIC inhibitors in this study maintained high gut microbial diversity, as well as preserved microbiome metabolic function, in contrast to the marked disruption shown by linezolidPol IIIC inhibitor compounds specifically preserved anaerobic microbiome

8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI from two agents to onePATHFINDER by itself  in patients with multiply-recurrent CDI will inform elements of a planned active-controlled, Phase 3 registration trial in  rCDI. Upon subsequent successful completion of PATHFINDER, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway fo

EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

The microbiome of patients experiencing recurrent CDI is frequently dominated by overgrowths of Enterococcus speciesThis study evaluated the in vitro bactericidal and molecular efficacy of ibezapolstat (IBZ), vancomycin (VAN), and fidaxomicin (FDX) against C. difficile and Enterococcus in standalone and complex co-culture environmentsThese findings demonstrate that Enterococcus creates a protective microenvironment that actively impairs C. difficile killing using standard of care antibiotic regimensIBZ maintained superior bactericidal activity under co-culture conditions, including further decreasing Clostridioides difficile toxin B (TcdB) expression while simultaneously eradicating vancomyc

S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

DEFA14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

DEF 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in C. difficile Infection (CDI)As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDASTATEN ISLAND, N.Y., Aug. 17, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or th

STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.   Highlights of the second quarter ended June 30, 2026, or in some cases shortly thereafter, include:In April 2026, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-m

10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Japan Patent Office and the Mexico Patent Office, respectively, have each granted a new patent which covers Acurx's DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to the Company's expanding series of granted patents in the U.S. and abroad. To da

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and AcurxThis prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC (pol IIIC, also known as PolC), with mechanistic findings that explain its properties of lacking cross-resistance with other antibiotics and not fostering the emergence of vancomycin-resistant Enterococcus strains, a unique differentiation among anti-CDI antibioticsThe new research partnership aims to generate the first-ever 3D structure of PolC from methicillin-resistant Staph

Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support indications for both treatment and reduction of recurrence of Clostridioides difficile infection (CDI)FDA stated that it is open to further discussion on the totality of evidence from the clinical development program at a pre-NDA meeting after completion of a single Phase 3 trial and any other clinical trials conducted prior to the pre-NDA meeting, particularly if the clinical efficacy results are robustAddi

Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin (VAN) and/or fidaxomicin (FDX)Following acute treatment with ibezapolstat (IBZ), these beneficial microorganisms will have the opportunity to repopulate the microbiome in a beneficial way that may prevent recurrenceIBZ and FDX were superior in biofilm experimental models with IBZ significantly more effective at killing C. difficile than VAN and FDXTrial start-up activities for a ground-breaking clinical trial in patients with multiply-recurrent CDI (rCDI) have been initiated with the first patient expected to enro

STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2026 financial results on Friday, August 14, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:               Friday, August 14, 2026  Time:               8:00 a.m. ET    Toll free (U.S.

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitorsLUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteriaHigh-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2ÅThe Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a devel

424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2026.   Highlights of the first quarter ended March 31, 2026, or in some cases shortly thereafter, include:In February 2026, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to December 2039, subject to extension under US patent rules. This adds to our extensi